Regarding treatment with [177Lu]Lu-PSMA-617, impressive results were obtained in PSMA-positive metastatic castration-resistant PCa (mCRPC) patients who received [177Lu]Lu-PSMA-617 plus standard of care versus standard of care treatment alone; with significantly prolonged progression-free survival and overall survival of 8.7 vs. 3.4 months and 15.3 vs. 11.3 months, respectively (12). The gene discussed is FOLH1; the disease is posterior cortical atrophy.